TY - JOUR T1 - Evaluation of Myocardial Perfusion and Immune Cell Response in Cardiac Allograft Dysfunction of Heart-Transplant Patients JF - medRxiv DO - 10.1101/2020.01.28.20018168 SP - 2020.01.28.20018168 AU - Paul J. Kim AU - Francisco Contijoch AU - Gerald Morris AU - Darrin Wong AU - Patricia Nguyen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/30/2020.01.28.20018168.abstract N2 - Background We investigated the myocardial perfusion differences and changes in immune cell response in heart-transplant patients with nonspecific graft dysfunction (NGD) compared to cardiac allograft vasculopathy (CAV) patients and normal heart-transplant patients.Methods and Results We prospectively studied 17 heart-transplant patients (59.8±14.1 years, 78% male) from January to June 2016. Regadenoson stress cardiac MRI was performed in the patients and peripheral blood obtained contemporaneously to isolate peripheral blood mononuclear cells (PBMCs). Stress myocardial perfusion showed significantly decreased myocardial perfusion using maximum upslope method in NGD and CAV patients compared to normal heart-transplant patients. Myocardial scar by late gadolinium enhancement also was significantly increased in nonspecific graft dysfunction patients compared to normal. Evaluation of PBMCs by flow cytometry showed a trend towards increased activated HLA-DR+ T cells in NGD patients compared to normal. Clinical outcomes for cardiac hospitalization, allograft loss/retransplant, death were assessed at 3 years.Conclusions NGD shows decreased stress myocardial perfusion by cardiac MRI and a trend towards increased activated T cells in PBMCs, suggestive of an immune-mediated cause for allograft dysfunction.Competing Interest StatementPaul Kim was supported by Astellas Pharma Investigator Sponsored Research. Astellas Pharma did not restrict review or publication of this data in any way.Clinical TrialNCT03102125Funding StatementPaul Kim was supported by Astellas Pharma Investigator Sponsored Research, Stanford Translational Research and Applied Medicine Pilot Grant, American Heart Association Career Development Award 18CDA34110250.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data is publicly available through Mendeley Data, an open access repository ER -